7.2988
20.90%
1.2688
前日終値:
$6.03
開ける:
$6.09
24時間の取引高:
899.13K
Relative Volume:
1.77
時価総額:
$378.12M
収益:
-
当期純損益:
$-117.81M
株価収益率:
11.40
EPS:
0.64
ネットキャッシュフロー:
$74.30M
1週間 パフォーマンス:
+4.89%
1か月 パフォーマンス:
+77.81%
6か月 パフォーマンス:
+116.97%
1年 パフォーマンス:
+333.93%
Omeros Corporation Stock (OMER) Company Profile
名前
Omeros Corporation
セクター
電話
206-676-5000
住所
201 ELLIOTT AVENUE WEST, SEATTLE, WA
OMER を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
OMER | 7.29 | 378.12M | 0 | -117.81M | 74.30M | 0.64 |
VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 747.38 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.68 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-12-08 | ダウングレード | UBS | Buy → Neutral |
2022-11-08 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-06-08 | ダウングレード | BofA Securities | Buy → Neutral |
2021-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
2021-10-01 | ダウングレード | Maxim Group | Buy → Hold |
2021-10-01 | ダウングレード | Wedbush | Neutral → Underperform |
2021-09-27 | 開始されました | JP Morgan | Neutral |
2021-02-01 | 開始されました | UBS | Buy |
2020-10-20 | 開始されました | BofA Securities | Buy |
2020-08-21 | 繰り返されました | H.C. Wainwright | Buy |
2020-08-14 | 繰り返されました | Maxim Group | Buy |
2019-05-06 | 開始されました | Cantor Fitzgerald | Overweight |
2018-07-12 | 開始されました | Seaport Global Securities | Buy |
2018-03-23 | ダウングレード | Wedbush | Outperform → Neutral |
2018-03-05 | ダウングレード | Needham | Buy → Hold |
2017-11-08 | 開始されました | H.C. Wainwright | Buy |
2017-05-11 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
2017-03-17 | 繰り返されました | Maxim Group | Buy |
2017-03-17 | 繰り返されました | Needham | Buy |
2016-11-16 | 繰り返されました | Wedbush | Outperform |
2016-11-10 | 繰り返されました | Needham | Buy |
2016-08-10 | 繰り返されました | Maxim Group | Buy |
2016-06-03 | 開始されました | Cantor Fitzgerald | Buy |
2016-03-02 | 繰り返されました | Needham | Buy |
2016-02-29 | 繰り返されました | Wedbush | Outperform |
2015-11-11 | 繰り返されました | Needham | Buy |
2015-08-18 | 繰り返されました | WBB Securities | Strong Buy |
2015-08-10 | 開始されました | ROTH Capital | Buy |
すべてを表示
Omeros Corporation (OMER) 最新ニュース
Omeros nears resubmission of narsoplimab BLA - Investing.com
Omeros Corporation Provides Update on Progress Toward BLA Resubmission - Yahoo Finance
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
StockNews.com Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat
IgA Nephropathy Drugs Market: Driving Rapid Expansion with - openPR
Omeros Q3 2024Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns (OMER) - Seeking Alpha
Data Storage Corporation Reports 2024 Third Quarter Financial Results and Provides Business UpdateWASHINGTON, D.C. – Data Storage Corporation (NASDAQ: DTST) released its financial results for the third quarter ending September 30, 2024, and provi - Defense World
SigmaTron International, Inc. Announces Departure and Appointment of Chief Financial OfficerUNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_______________FORM 8-K_______________CURRENT REPORTPurs - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
Sydney high school parents vent frustration at plan for single-sex schools to become co-educational - ABC News
Omeros (NASDAQ:OMER) Upgraded at RODMAN&RENSHAW - MarketBeat
United States shares lower at close of trade; Dow Jones Industrial Average down 0.47% - Investing.com India
Omeros stock soars to 52-week high, hits $5.68 By Investing.com - Investing.com Canada
Earnings call: Omeros narrows Q3 loss, progresses key drug programs By Investing.com - Investing.com Australia
Earnings call: Omeros narrows Q3 loss, progresses key drug programs - Investing.com India
Omeros (OMER) Stock Rises After Reporting Q3Results - Stocks Telegraph
Omeros Shares Hit 52-Week High on Plan to Resubmit Narsoplimab Application - MarketWatch
U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn
Rodman & Renshaw sets $9 target on Omeros stock with Buy rating - Investing.com
Omeros' (OMER) "Neutral" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Omeros stock soars to 52-week high, hits $5.68 - Investing.com
500: Something went wrong - Investing.com UK
U.S. Stock market top gainers: AgEagle Aerial Systems surges by 151.55% while Gaxos.ai Inc gains 47.58% in ealry trading - Business Upturn
Needham & Company LLC Reaffirms "Hold" Rating for Omeros (NASDAQ:OMER) - MarketBeat
Omeros initiated with a Buy at Rodman & Renshaw - TipRanks
Omeros (NASDAQ:OMER) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Omeros: Q3 Earnings Snapshot - New Haven Register
Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments - Yahoo Finance
Omeros Corporation Q3 2024 Financial Results Reviewed - TipRanks
Omeros up 4% as Q3 results beat on EPS - MSN
Omeros reports Q3 EPS (56c), two estimates (70c) - TipRanks
Q3 2024 Omeros Corp Earnings Call Transcript - GuruFocus.com
Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Omeros Q3 Loss Narrows to $32.2M, Advances Key Drug Programs Amid FDA Talks | OMER Stock News - StockTitan
Omeros Corporation Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Blackline, Inc. Appoints Philippe Omer Decugis as Senior Vice President for Europe - Marketscreener.com
Earnings Outlook For Omeros - Benzinga
Omeros (OMER) Set to Announce Earnings on Wednesday - MarketBeat
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024 - Business Wire
Week Ahead In Pharmaceuticals: 5 Stocks To Watch (OMER, BOLD, XLRN...) - RTTNews
Omeros (NASDAQ:OMER) Stock Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Cardiff City board to hold meeting with Omer Riza this weekend - Wales Online
Atypical Hemolytic Uremic Syndrome Drugs Market 2034: - openPR
NVIDIA Co. (NASDAQ:NVDA) Stock Holdings Increased by Alpha DNA Investment Management LLC - Defense World
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Focal Segmental Glomerulosclerosis Drugs Market Report 2024FSGS Drugs Market Size - WhaTech
Global Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Reach USD 2308.84 Million by 20 - PharmiWeb.com
Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy - Pharmacy Times
OMEROmeros Corporation Latest Stock News & Market Updates - StockTitan
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy - Business Wire
Global Alcohol Use Disorder Treatment Market to Reach USD 1,300 million by 2033 at a 6.4% CAGR, Driv - PharmiWeb.com
Omeros Corporation (OMER) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):